Abstract
The new in vitro activity of temocillin (BRL 17421), a new beta-lactamase-stable penicillin, was compared with those of other beta-lactam antibiotics for over 500 clinical bacterial isolates. Temocillin inhibited 94% of the Enterobacteriaceae organisms at concentrations of 0.5 to 8 microgram/ml, regardless of organisms resistance to ampicillin, ticarcillin, cefazolin, or combinations thereof. Most pseudomonas aeruginosa isolates and all staphylococci and streptococci tested were resistant to temocillin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Slocombe B., Basker M. J., Bentley P. H., Clayton J. P., Cole M., Comber K. R., Dixon R. A., Edmondson R. A., Jackson D., Merrikin D. J. BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother. 1981 Jul;20(1):38–46. doi: 10.1128/aac.20.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Verbist L., Verhaegen J. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother. 1980 May;17(5):807–812. doi: 10.1128/aac.17.5.807. [DOI] [PMC free article] [PubMed] [Google Scholar]